BioWorld
-
FDA issues CRL for Enzyvant's congenital athymia therapy
-
Borealis keys to palace: Aurinia’s Aurora phase III bid with voclosporin lights up LN
-
Scaling the Mountain: Sage study marks a primary endpoint miss
-
Worth the wait, Acadia’s Nuplazid looks good in dementia-related psychosis
-
Cancer-focused Black Diamond raises $85M series C
-
4Teen4 closes $8M A round to test first-in-class cardiogenic shock drug
-
Rapt licenses FLX-475 to Hanmi in deal worth up to $118M
-
Akoya Biosciences rakes in $50M to back CODEX, Phenoptics platforms
-
Omeros touts pivotal data on HSCT-TMA candidate, shielding details
BioWorld MedTech
-
Akoya Biosciences rakes in $50M to back CODEX, Phenoptics platforms
-
Micro-leads raises $10M to develop and test precision spinal cord stimulation
-
Boston Sci’s Watchman scores well at 50 months for hemorrhagic stroke
-
DHIT, Tanjo team up to improve health via HUG in North Carolina
-
Bioworld MedTech’s Diagnostics Extra for Dec. 5, 2019
-
BioWorld MedTech Patent Highlights - Week 48
-
Veracyte seeks wider diagnostics footprint with Nanostring licensing deal
-
China’s Genskey raised $14M in series B to advance pathogen testing
-
Solicitor General fails to respond to petition for cert in Athena v. Mayo
BioWorld Asia
-
Celltrion’s Remsima SC wins marketing approval in EU
-
China updates reimbursement drug list, further encourages innovation at home
-
GI Innovation licenses GI-101 to Simcere at maximum $796 million
-
Australia’s Opthea raises AU$50M to advance OPT-302 to phase III in wet AMD
-
Indian pharma sector needs to learn from its competitors: report
-
In India, government steps up efforts to develop more TB testing and treatment
